Deep generative neural network for accurate drug response imputation
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Deep generative neural network for accurate drug response imputation
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-19
DOI
10.1038/s41467-021-21997-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Visualizing and interpreting cancer genomics data via the Xena platform
- (2020) Mary J. Goldman et al. NATURE BIOTECHNOLOGY
- Kinase-targeted cancer therapies: progress, challenges and future directions
- (2018) Khushwant S. Bhullar et al. Molecular Cancer
- The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations
- (2018) Alexandra B. Keenan et al. Cell Systems
- Systematic identification of non-coding pharmacogenomic landscape in cancer
- (2018) Yue Wang et al. Nature Communications
- Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies
- (2017) Paul Geeleher et al. GENOME RESEARCH
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Tissue specificity of in vitro drug sensitivity
- (2017) Fupan Yao et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- Evaluating the molecule-based prediction of clinical drug responses in cancer
- (2016) Zijian Ding et al. BIOINFORMATICS
- Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes
- (2016) Andriy Marusyk et al. CANCER RESEARCH
- Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm
- (2016) M. L. Turski et al. MOLECULAR CANCER THERAPEUTICS
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- A gene-based association method for mapping traits using reference transcriptome data
- (2015) Eric R Gamazon et al. NATURE GENETICS
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy
- (2015) Feixiong Cheng et al. Oncotarget
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma
- (2014) Nishant Agrawal et al. CELL
- WWOX: A fragile tumor suppressor
- (2014) Morgan S Schrock et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer
- (2012) Tomohiro Miyake et al. CANCER SCIENCE
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
- (2012) Wanjuan Yang et al. NUCLEIC ACIDS RESEARCH
- A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
- (2011) Christos Hatzis JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
- (2011) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
- (2010) J. R. Dry et al. CANCER RESEARCH
- HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
- (2009) Britta Weigelt et al. BREAST CANCER RESEARCH AND TREATMENT
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
- (2009) Pierre Farmer et al. NATURE MEDICINE
- Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer
- (2008) O. Gautschi et al. CANCER RESEARCH
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started